Justification of optimal period for vitreoretinal intervention on the background of preoperative anti-VEGF therapy for proliferative diabetic retinopathy

    Abstract

    Justification of optimal period for vitreoretinal intervention on the background of preoperative anti-VEGF therapy for proliferative diabetic retinopathy

    M.M. Bikbov, M.R. Kalanov, T.R. Gilmanshin, R.M. Zainullin, K.I. Kudoyarova, T.A. Khalimov

    Ufa Eye Research Institute, Ufa

    Purpose. Determine the optimal time for vitreoretinal intervention in the presence of preoperative anti-VEGF therapy in patients with proliferative diabetic retinopathy.

    Material and methods. In total, 30 patients (30 eyes) with PDD against type 2 diabetes mellitus took part in this study. Of these, 24 women (80.0%), men – 6 (20.0%). Anti-VEGF therapy included intravitreal administration (IVV) of ranibizumab at a dose of 0.5 mg (0.05 ml) once.

    Results. The maximum regression of neovascularization and decrease in retinal thickness in the macular region was observed from the 10th day. An increase in the traction effect on the retina was noted on the 15th day, the peak of which was fixed closer to the 23rd day after the injection of angiogenesis inhibitors. An increase in the distance and increase in the traction component on the complex «fibroglial tissue – macular region» was noted from the 15th day after intravitreal injection of ranibizumab.

    Conclusion. The presented study showed that the most optimal time for vitreoretinal intervention in patients with proliferative diabetic retinopathy is 10-14 days after the intravitreal administration of angiogenesis inhibitors.

    Key words: proliferative diabetic retinopathy, preoperative anti-VEGF therapy, neovascularization, traction syndrome, vitreomacular interface.